Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

184
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
184
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

143
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
143
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

111
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
111
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

133
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
133
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

170
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
170
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

159
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
159

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

Clinical pharmacology and therapeutics·2026
Same author

Repeat CRP measurements and incident myocardial infarction.

American journal of preventive cardiology·2026
Same author

Dialysis Modality, Adequacy and the ESRD Quality Incentive Program Score.

Kidney medicine·2026
Same author

Representation of Older Adult Patients in Clinical Trials.

Clinical and translational science·2025
Same author

Detecting and Mapping Invasive Species Across Riparian Corridors via Object Detection Approaches in UAV Imagery: An Example of <i>Impatiens glandulifera</i>.

Ecology and evolution·2025
Same author

Therapeutic drug monitoring-Does it really matter?

British journal of clinical pharmacology·2024

Related Experiment Video

Updated: Dec 20, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.3K

A Real-World Evidence Framework for Optimizing Dosing in All Patients With COVID-19.

Richard W Peck1, Daniel Weiner2, Jack Cook3

  • 1Clinical Pharmacology, Pharma Research & Early Development, Roche Innovation Center, Basel, Switzerland.

Clinical Pharmacology and Therapeutics
|May 24, 2020
PubMed
Summary

Developing optimal dosing information for coronavirus disease 2019 (COVID-19) treatments is crucial for safe and effective patient use. Rapid collaboration among drug developers, academics, and regulators is essential for timely updates.

More Related Videos

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

4.3K

Related Experiment Videos

Last Updated: Dec 20, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.3K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

4.3K

Area of Science:

  • Pharmacology and Drug Development
  • Infectious Diseases
  • Public Health

Background:

  • The rapid development of potential treatments for coronavirus disease 2019 (COVID-19) necessitates swift strategies for their clinical application.
  • Ensuring the safe and effective use of these treatments across diverse patient populations is a significant challenge.

Purpose of the Study:

  • To highlight the urgent need for developing dynamic dosing guidelines for COVID-19 therapies.
  • To emphasize the requirement for rapid, updated dosing information tailored to various patient subgroups.

Main Methods:

  • This study is a conceptual analysis and call for action, outlining the necessity for advanced pharmacokinetic and pharmacodynamic modeling.
  • It emphasizes the need for real-time data integration and adaptive trial designs.

Main Results:

  • Successful COVID-19 treatments will be deployed to hundreds of thousands of patients, demanding precise dosing.
  • Optimal dosing information must be frequently updated to account for evolving clinical data and patient variability.

Conclusions:

  • Immediate and unprecedented collaboration between drug developers, academic researchers, and regulatory agencies is paramount.
  • Establishing a rapid system for disseminating updated dosing recommendations is critical for maximizing treatment efficacy and patient safety in the COVID-19 pandemic.